Rheumatoid arthritis does not develop overnight. By the time a diagnosis is made, inflammation has often been present for some time, even though it is not yet visible on the outside. Ideally patients at risk for RA are recognized and treated in this at-risk phase in order to prevent progression to clinically apparent disease. New research shows that this approach can improve outcomes in ACPA-negative patients and may even prevent rheumatoid arthritis.
Read more&width=710&height=710)
A driving force
LUMC strongly underpins the idea that ‘Science is the driving force behind innovative healthcare’. Outcomes of top level fundamental, translational and clinical research by LUMC researchers form a strong basis for innovative and qualitative healthcare on a national, European and international level.
A real game changer was the development of the Dutch national research agenda (NWA) in 2015. The agenda reveals the complexity of the issues challenging Dutch society today. These issues are clustered in so called routes. LUMC is involved in many of these routes and contributes this way to solving important societal challenges.